Merck to Acquire Immune Design
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
RBC Capital Downgrades Immune Design (IMDZ) to Sector Perform Following Takeover Deal
February 22, 2019 6:34 AM ESTRBC Capital analyst Brian Abrahams downgraded Immune Design (NASDAQ: IMDZ) from Outperform to Sector Perform with a price target of $6.00 (from $9.00).
The see the acquisition by MRK as highly likely to go through.
For an analyst ratings summary and ratings... More
Immune Design (IMDZ) to be Acquired by Merck for Massive Premium, Shares Surge
February 21, 2019 6:47 AM ESTImmune Design (NASDAQ: IMDZ) to be Acquired by Merck for Massive Premium, Shares Surge
... More